Virologist treats breast cancer with oncolytic virotherapy, shrinking the tumor and boosting immune response. An ...

Virologist Beata Halassy, ​​facing a recurrent tumor, develops and tests on herself an innovative therapy: here is her story.

About MB-109 (MB-101 (IL13Rα2 targeted CAR-T cells) + MB-108 oncolytic virus) ...

Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex ...

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...

Clinical-stage immuno-oncology company Imugene is celebrating more than two years’ “complete response” for one of its bile ...

Imugene stocks well placed to grow with clinical progress on azer-cel CAR T-cell therapy and strong cash position, say analysts ...

Researchers have engineered an adenovirus to selectively target and kill aggressive brain cancer cells, which has shown ...

Researchers from Queen Mary University of London, the Chinese Academy of Sciences and Capital Medical University in Beijing ...

The Phase-1 OASIS (oncolytic assessment and safety in solid tumours ... and intravenous (IV) administrations of the therapy, ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

In addition, Imugene has made strides in expanding its trial. The Cohort Review Committee has cleared the first cohort of ...